Secnidazole

Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) in Adolescents for both the Treatment of Bacterial Vaginosis in Females and Trichomoniasis

Retrieved on: 
Thursday, February 17, 2022
Energy drink, Woman, Propylene glycol, Prevalence, Abdominal pain, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lupinus, Liver failure, Yogurt, Risk, Private Securities Litigation Reform Act, Gaps, Cockayne syndrome, Trichomoniasis, Health, New Drug Application, Vaginitis, Sex, Patient, Bacterial vaginosis, Shanda, Candidiasis, Diarrhea, Female, National Health and Nutrition Examination Survey, Vertically transmitted infection, BV, Patent, Ethanol, Lupin Limited, Sexually transmitted infection, Human, Metronidazole, Headache, Infection, CDC, Incidence, Vomiting, Vaginal yeast infection, National Health, Secnidazole, Reproductive health, Food, Environment, STI, FDA, Prescription, Nausea, Partner (business rank), Dysgeusia, Pharmaceutical industry, Birth control, Legume, Adolescence

"The FDA's approval expands the indication for SOLOSEC to treat adolescents and builds upon our commitment to support women's health.

Key Points: 
  • "The FDA's approval expands the indication for SOLOSEC to treat adolescents and builds upon our commitment to support women's health.
  • Vulvovaginal candidiasis may develop with SOLOSEC and require treatment with an antifungal agent.
  • To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-844-SOLOSEC (1-844-765-6732) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
  • SOLOSEC is a registered trademark of Lupin Inc. and LUPIN is a registered trademark of Lupin Pharmaceuticals, Inc.

Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® (secnidazole) expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis

Retrieved on: 
Thursday, January 27, 2022
History, Central nervous system, Infection, Risk, Vomiting, Patent, Partner (business rank), Propylene glycol, Patient, Reproductive health, Trichomoniasis, Birth, Hypersensitivity, Candidiasis, Private Securities Litigation Reform Act, BV, Menopause, Yogurt, FDA, Secnidazole, Prescription, CDC, Transmission, Abdominal pain, Prevalence, Nausea, Adult, Bacterial vaginosis, Ethanol, Independent Healthcare Providers Network, Fertility, Incidence, Pregnancy, Diarrhea, Solution, Woman, Human, Vaginal yeast infection, Headache, Women's health, Lupin Limited, Energy drink, Dysgeusia, Environment, Health, Vaginitis, CNS, Partnership, Birth control, Pharmaceutical industry, Risk management, Legume, Ophthalmology, Endocrinology

Exeltis' overarching goal is to support and care for women throughout every stage of life.

Key Points: 
  • Exeltis' overarching goal is to support and care for women throughout every stage of life.
  • [1]
    SOLOSEC (secnidazole) 2 g oral granules is an antimicrobial agent indicated for the treatment of bacterial vaginosis in adult women and trichomoniasis in adults.
  • SOLOSEC is a registered trademark of Lupin Inc. and LUPIN is a registered trademark of Lupin Pharmaceuticals, Inc.
  • The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health.

Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) for the Treatment of Trichomoniasis

Retrieved on: 
Thursday, July 1, 2021
Medical specialties, Infectious diseases, Sexually transmitted diseases and infections, Antiprotozoal agents, Nitroimidazole antibiotics, Clinical medicine, Infectious causes of cancer, Bacterial vaginosis, Mycoplasma, Trichomoniasis, Secnidazole

[1] SOLOSEC was approved in the U.S. in 2017 for the treatment of bacterial vaginosis (BV) in adult women.

Key Points: 
  • [1] SOLOSEC was approved in the U.S. in 2017 for the treatment of bacterial vaginosis (BV) in adult women.
  • The supplemental approval makes SOLOSEC the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV.
  • Research demonstrates that approximately 70% of women with trichomoniasis are PCR positive for BV,[2]" said Jon Stelzmiller, President Specialty, Lupin Pharmaceuticals, Inc.
  • SOLOSEC(secnidazole) 2 g oral granules is an antimicrobial agent indicatedfor the treatment of BV in adult women and trichomoniasis in adults.

Lupin Announces SOLOSEC® (secnidazole) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.

Retrieved on: 
Wednesday, April 22, 2020
RTT, Antiprotozoal agents, Nitroimidazole antibiotics, Secnidazole, Medical specialties, Disulfiram-like drugs, Bacterial vaginosis, Nitroimidazole, Antimicrobial, Health, Biology

As a preferred medication, Solosec will be available at a lower out-of-pocket cost to the represented Express Scripts plan members compared to BV medications which are non-preferred or excluded.

Key Points: 
  • As a preferred medication, Solosec will be available at a lower out-of-pocket cost to the represented Express Scripts plan members compared to BV medications which are non-preferred or excluded.
  • "We believe our pricing and access strategy prioritizes patients by providing a novel, first-of-its-kind BV treatment at pricing designed to reduce barriers to treatment with Solosec."
  • SOLOSEC (secnidazole) 2g oral granules is a 5-nitroimidazole antimicrobial agent indicated for the treatment of bacterial vaginosis (BV) in adult women.
  • SOLOSEC is contraindicated in patients with a history of hypersensitivity to secnidazole, other ingredients of the formulation, or other nitroimidazole derivatives.